Evidence map›Paper›PMID 36273122›Full record

ArticleCellular & molecular biology letters2022

Down-regulation of EVA1A by miR-103a-3p promotes hepatocellular carcinoma cells proliferation and migration.

Qian Xu, Zhaozhong Liao, Zunshuang Gong, Xiaokun Liu, Yuling Yang, Zhe Wang, Weiyan Yang, Lin Hou, Jiejie Yang, Junying Song and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cellular & molecular biology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. A Novel Bromophenol Compound fromMolecules (Basel, Switzerland) · 2023
    Article
  15. Review
  16. NJournal of hepatocellular carcinoma · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Qian Xu *Department of Biochemistry and Molecular Biology, School of Basic Medicine, Qingdao University, Qingdao, China.
Zhaozhong Liao *Department of Biochemistry and Molecular Biology, School of Basic Medicine, Qingdao University, Qingdao, China.
Zunshuang Gong *Department of Biochemistry and Molecular Biology, School of Basic Medicine, Qingdao University, Qingdao, China.
Xiaokun LiuDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Qingdao University, Qingdao, China.
Yuling YangDepartment of Infectious Diseases, Affiliated Hospital of Qingdao University, Qingdao, China.
Zhe WangDepartment of Biotechnology, School of Basic Medicine, Qingdao University, Qingdao, China.
Weiyan YangDepartment of Anesthesiology, Family Planning Service Center, Maternal and Child Health Hospital of Jiaozhou City, Qingdao, China.
Lin HouDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Qingdao University, Qingdao, China.
Jiejie YangDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Qingdao University, Qingdao, China.
Junying SongDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Qingdao University, Qingdao, China.
Wenjing LiuDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Qingdao University, Qingdao, China.
Bin WangCollege of Electronic Information, Micro-Nano Technology College, Qingdao University, Qingdao, China.
Junnan HuaDepartment of Biotechnology, School of Basic Medicine, Qingdao University, Qingdao, China.
Mingyi PuDepartment of Infectious Diseases, Affiliated Hospital of Qingdao University, Qingdao, China.
Ning LiDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Qingdao University, Qingdao, China. ning-99@163.com.ORCID http://orcid.org/0000-0002-1895-4983
Qingdao University · CN

Funding

Key Technologies Research and Development Program 2018YFA0109800National Natural Science Foundation of China 81600470Shandong Provincial Natural Science Foundation, China ZR2022MC053
6 · The paper itself

Abstract

backgroundEVA1A (Eva-1 homolog A), a novel protein involved in autophagy and apoptosis, functions as a tumor suppressor in some human primary cancers, including hepatocellular carcinoma (HCC). While it is consistently downregulated in several cancers, its involvement in hepatocarcinogenesis is still largely unknown.

methodsWe first detected the expression of EVA1A in HCC tissues and cell lines using RT‒qPCR, immunohistochemistry and western blotting and detected the expression of miR-103a-3p by RT‒qPCR. Then, bioinformatics prediction, dual-luciferase reporter gene assays and western blotting were used to screen and identify the upstream microRNA of EVA1A. After manipulating the expression of miR-103a-3p or EVA1A, wound healing, invasion, proliferation, colony formation, apoptosis, autophagy, mitosis and mitochondrial function assays, including mitochondrial membrane potential, ROS and ATP production assays, were performed to investigate the functions of miR-103a-3p targeting EVA1A in HCC cells. Apoptosis-related proteins were assessed by RT‒qPCR (TP53) or western blotting (TP53, BAX, Bcl-2 and caspase-3). Autophagy level was evaluated by observing LC3 puncta and examining the protein levels of p62, Beclin1 and LC3-II/I.

resultsWe found that EVA1A expression was decreased while miR-103a-3p expression was increased in HCC tissues and cell lines and that their expression was inversely correlated in HCC patients. The expression of miR-103a-3p was associated with HCC tumor stage and poor prognosis. miR-103a-3p could target EVA1A through direct binding to its 3'-UTR and suppress its expression. Overexpression of miR-103a-3p significantly downregulated the expression of EVA1A, TP53 and BAX, upregulated the JAK2/STAT3 pathway and promoted HCC cell migration, invasion and proliferation, while repression of miR-103a-3p dramatically upregulated the expression of EVA1A, TP53, BAX and cleaved-caspase-3, inhibited HCC cell migration, invasion and proliferation, and caused mitochondrial dysfunction and apoptosis. Overexpression of EVA1A significantly attenuated the cancer-promoting effects of miR-103a-3p in HCC cells, while knockdown of EVA1A alleviated the mitochondrial dysfunction and apoptosis caused by miR-103a-3p inhibition. Overexpression of EVA1A did not induce significant changes in autophagy levels, nor did it affect G2/M transition or mitosis.

conclusionThese findings indicate that the downregulation of the tumor suppressor EVA1A by miR-103a-3p potentially acts as a key mediator in HCC progression, mainly by inhibiting apoptosis and promoting metastasis. The miR-103a/EVA1A/TP53 axis provides a new potential diagnostic and therapeutic target for HCC treatment.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAs3' Untranslated RegionsAdenosine Triphosphatebcl-2-Associated X ProteinBeclin-1Caspase 3Cell Line, TumorCell MovementCell ProliferationDown-RegulationGene Expression Regulation, NeoplasticHumansLuciferasesMembrane Proteins3' Untranslated RegionsAdenosine Triphosphatebcl-2-Associated X ProteinBeclin-1Caspase 3EVA1A protein, humanLuciferasesMembrane ProteinsMicroRNAsMIRN103A2 microRNA, humanReactive Oxygen SpeciesApoptosisAutophagyEVA1Ahepatocellular carcinomamiR-103a-3pMitosisTP53

Identifiers

PMID36273122
PMCPMC9588234
OpenAlexW4307136182

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.